Alnylam Pharmaceuticals, Inc.
NASDAQ:ALNY · NASDAQ Global Select
-$6.27 today
Vol 1.77M · Avg 1.11M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:ALNY · Revenue to Net Income
Key Ratios
Analysis
$4.3B of revenue converted into $577.2M of net income for the selected period. Gross margin is 80.8% and net margin is 11.5%, showing how much revenue survives after costs and taxes. EPS is $4.21, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.7B +65.2% | $2.2B +23.0% | $1.8B +76.2% | $1.0B +22.9% | $844.3M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $677.2M +109.4% | $323.4M +4.2% | $310.4M +83.9% | $168.8M +20.5% | $140.1M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $3.0B +57.8% | $1.9B +26.8% | $1.5B +74.8% | $868.6M +23.4% | $704.1M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 81.8% -3.8pp | 85.6% +2.6pp | 83.0% -0.7pp | 83.7% +0.3pp | 83.4% | 9.8% | 28.9% | 38.3% |
| Research & Development | $1.3B +17.6% | $1.1B +12.1% | $1.0B +13.7% | $883.0M +11.5% | $792.2M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $1.2B +24.1% | $975.5M +22.6% | $795.6M +3.2% | $770.7M +24.2% | $620.6M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $2.5B +20.6% | $2.1B +16.8% | $1.8B +8.9% | $1.7B +17.0% | $1.4B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $55.7M -1.8% | $56.7M +4.8% | $54.1M +21.6% | $44.5M -6.5% | $47.6M | $374.2M | $1.2B | $631.8M |
| EBITDA | $631.4M +453.1% | -$178.8M +30.7% | -$258.2M +72.1% | -$926.6M -40.1% | -$661.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 17.0% +25.0pp | -8.0% +6.2pp | -14.1% +75.2pp | -89.3% -11.0pp | -78.4% | 5.6% | 46.3% | 42.0% |
| Operating Income | $501.6M +383.6% | -$176.9M +37.3% | -$282.2M +64.1% | -$785.1M -10.8% | -$708.7M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 13.5% +21.4pp | -7.9% +7.6pp | -15.4% +60.2pp | -75.7% +8.3pp | -83.9% | 16.6% | 24.1% | 22.0% |
| Interest Income | $111.5M -8.6% | $122.0M +27.7% | $95.6M +285.2% | $24.8M +1471.1% | $1.6M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $252.6M +78.1% | $141.9M +17.0% | $121.2M -22.3% | $156.0M +9.1% | $143.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$178.4M +11.0% | -$200.5M -32.5% | -$151.3M +55.7% | -$341.9M -138.3% | -$143.5M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $323.2M +185.6% | -$377.4M +13.0% | -$433.5M +61.5% | -$1.1B -32.3% | -$852.1M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 8.7% +25.5pp | -16.8% +6.9pp | -23.7% +84.9pp | -108.6% -7.7pp | -100.9% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $9.4M +109.5% | -$99.2M -1575.4% | $6.7M +61.5% | $4.2M +512.2% | $680.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | $313.7M +212.8% | -$278.2M +36.8% | -$440.2M +61.1% | -$1.1B -32.6% | -$852.8M | $4.9B | $4.8B | $4.7B |
| Net Margin | 8.4% +20.8pp | -12.4% +11.7pp | -24.1% +85.0pp | -109.0% -8.0pp | -101.0% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $2 +209.6% | -$2 +38.1% | -$4 +62.2% | -$9 -29.2% | -$7 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $2 +206.9% | -$2 +38.1% | -$4 +62.2% | -$9 -29.2% | -$7 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $131.0M +2.6% | $127.7M +2.2% | $124.9M +2.6% | $121.7M +2.7% | $118.5M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $134.7M +5.5% | $127.7M +2.2% | $124.9M +2.6% | $121.7M +2.7% | $118.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Cigna Corporation
NYSE:CI
$74.25B
Regeneron Pharmaceuticals, Inc.
NASDAQ:REGN
$62.16B
argenx SE
NASDAQ:ARGX
$54.47B
Cencora, Inc.
NYSE:COR
$52.84B
Cardinal Health, Inc.
NYSE:CAH
$52.30B
Becton, Dickinson and Company
NYSE:BDX
$52.24B
Edwards Lifesciences Corporation
NYSE:EW
$50.28B
IDEXX Laboratories, Inc.
NASDAQ:IDXX
$44.08B
Zoetis Inc.
NYSE:ZTS
$32.85B
Veeva Systems Inc.
NYSE:VEEV
$24.76B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ALNY generate?
Alnylam Pharmaceuticals, Inc. (ALNY) reported $3.71B of revenue in fiscal 2025.
Is ALNY profitable?
Alnylam Pharmaceuticals, Inc. (ALNY) reported $313.75M of net income, with a net margin of 8.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.